OCS

Oculis Holding AG

Recommendation Details

PortfolioHealthcare

DateOct 29, 2026

ForecastQ Daily Probabilities

51.4%

34.7%

36.7%

Company Description

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Recent News & Events

Near-term catalysts skew positive, anchored by imminent Q4 2026 IND submission for privosegtor in acute MS relapses and fresh H.C. Wainwright Buy reiteration with $39 target; the May 2026 DIAMOND Phase 3 failure remains an overhang but is largely priced in.

Analyst Rating Reiteration

H.C. Wainwright reiterates Buy, $39 target on biomarker data

H.C. Wainwright reiterated a Buy rating and $39 price target (vs. ~$8.09 trading price) following new Phase 2 ACUITY biomarker analyses showing privosegtor reduced plasma neurofilament light chain and GFAP versus placebo. The endorsement reinforces the neuroprotective thesis ahead of the PIONEER registrational program and could support near-term buying interest given the large implied upside.

Investing.com

Regulatory Milestone (Upcoming IND Submission)

Q4 2026 IND submission planned for privosegtor in MS relapses

Following positive FDA pre-IND feedback, Oculis plans to submit an IND for privosegtor in acute MS relapses in Q4 2026, with no additional preclinical studies required and a potential 3-month primary endpoint. An imminent IND submission is a discrete, verifiable catalyst that could drive sentiment as the quarter progresses.

BioPharmaWatch

Clinical Trial Failure (Overhang)

Phase 3 DIAMOND trials fail primary endpoint for OCS-01

OCS-01 missed the primary visual acuity endpoint in both DIAMOND-1 and DIAMOND-2, and Oculis will not pursue an FDA filing in DME, driving a ~51% day-1 decline and peak drawdown of ~56%. The event is largely priced in but remains a lingering negative overhang and rationale for redirected resources to privosegtor and licaminlimab.

BioPharmaWatch

Clinical Trial Progress

First patient randomized in PREDICT-1 licaminlimab trial

Oculis randomized the first patient in the PREDICT-1 genotype-based registrational trial of licaminlimab in dry eye disease, advancing its second late-stage asset. Continued enrollment progress supports the pipeline narrative but is a slower-burn catalyst with limited immediate price impact.

BioPharmaWatch

OCS

OCS

Company Information

Recommendation Details

Company Description

Recent News & Events

H.C. Wainwright reiterates Buy, $39 target on biomarker data

Q4 2026 IND submission planned for privosegtor in MS relapses

Phase 3 DIAMOND trials fail primary endpoint for OCS-01

First patient randomized in PREDICT-1 licaminlimab trial